XML 24 R5.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Total revenue $ 0 $ 14,969
Operating expenses    
Research and development 25,564 42,236
General and administrative 40,830 29,670
Impairment of intangible assets 4,667 0
Goodwill impairment 0 12,209
Total operating expenses 71,061 84,115
Other operating income 506 1,176
Loss from operations (70,555) (67,970)
Other income/(expense):    
Interest income 1,957 2,678
Interest expense (51) (53)
Research and development incentives 2,000 3,983
Other income 16 135
Total other income, net 3,922 6,743
Loss before income tax (66,633) (61,227)
Tax benefit 175 44
Net loss (66,458) (61,183)
Net loss attributable to noncontrolling interest 30 109
Net loss attributable to Barinthus Biotherapeutics plc shareholders $ (66,428) $ (61,074)
Weighted-average ordinary shares outstanding, basic (in shares) 40,527,218 39,348,240
Weighted-average ordinary shares outstanding, diluted (in shares) 40,527,218 39,348,240
Net loss per share attributable to ordinary shareholders, basic (in usd per share) $ (1.64) $ (1.55)
Net loss per share attributable to ordinary shareholders, diluted (in usd per share) $ (1.64) $ (1.55)
Net loss $ (66,458) $ (61,183)
Other comprehensive gain/(loss) – foreign currency translation adjustments 10,145 (2,549)
Comprehensive loss (56,313) (63,732)
Comprehensive loss/(gain) attributable to noncontrolling interest 22 105
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders (56,291) (63,627)
License revenue    
Total revenue [1] $ 0 $ 14,969
[1] All license revenue is from related parties and is generated in the U.K. for the year ended December 31, 2024.